Nektar Therapeutics (NKTR) vs Replimune Group, Inc. (REPL)
A side-by-side comparison of Nektar Therapeutics and Replimune Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NKTR
Nektar Therapeutics
$39.70HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
REPL
Replimune Group, Inc.
$13.18HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
Total return — NKTR vs REPL
growth of $100 · dividends reinvested · last 8yNKTR -94.2% (-29.9%/yr)REPL -13.3% (-1.8%/yr)REPL compounded faster over this window
Log scale — wide-divergence pair
NKTR REPL
NKTR vs REPL: by the numbers
- •NKTR is the larger company ($1.14B vs $1.11B market cap).
- •Both run net losses; REPL's is the smaller (0.00% vs -287.84% net margin).
Metrics side by side
Valuation
| Metric | NKTR | REPL |
|---|---|---|
| P/S ratio | 20.86 | N/A |
| P/B ratio | 1.26 | 10.48 |
Profitability
| Metric | NKTR | REPL |
|---|---|---|
| Gross margin | 99.36% | 0.00% |
| Operating margin | -240.38% | 0.00% |
| Net margin | -287.84% | 0.00% |
| ROE | -17.40% | -281.14% |
| ROIC | -12.53% | -139.11% |
Growth (annualized)
| Metric | NKTR | REPL |
|---|---|---|
| Revenue CAGR (5Y) | -12.34% | N/A |
| Total return CAGR (5Y) | -30.33% | -15.17% |
Frequently asked
- How have NKTR and REPL total returns compared?
- Over the past 5 years, NKTR delivered -30.33% and REPL delivered -15.17% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.